Acurx Pharmaceuticals (ACXP)
(Delayed Data from NSDQ)
$2.17 USD
+0.05 (2.36%)
Updated May 3, 2024 04:00 PM ET
After-Market: $2.20 +0.03 (1.38%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ACXP 2.17 +0.05(2.36%)
Will ACXP be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ACXP based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ACXP
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference
Acurx presents ibezapolstat Phase 2 clinical trial results in CDI
Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference
Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update
Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket